GlassScriptPhysician profile
Durr-E-Shahwaar Sayed
NPI 1821228263
$2,413.34
in general payments reported to CMS, 2019-2025
26 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $167 · 2021: $283 · 2022: $352 · 2023: $309 · 2024: $434 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.08 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $431.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $307.31 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $200.39 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $138.47 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.97 | 2019-2021 | |
| Glaxosmithkline, LLC. | $101.40 | 2019-2023 | Bexsero, Pediarix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $76.92 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $75.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $65.91 | 2019-2020 | |
| Pfizer INC. | $55.25 | 2024-2025 | |
| Corcept Therapeutics | $43.31 | 2025 | Korlym |
| Medtronic, INC. | $39.41 | 2024 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $33.83 | 2023 | Quviviq |
| Exact Sciences Corporation | $32.36 | 2023 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $31.51 | 2024 | Injectafer |
| Amgen INC. | $27.89 | 2019-2022 | |
| Hologic Sales and Service, LLC | $22.12 | 2023 | Thinprep 2000 Processor |
| Inspire Medical Systems, INC. | $19.74 | 2024 | Inspire |
| Amneal Pharmaceuticals LLC | $18.69 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.08 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.06 | 2019 | |
| Allergan, INC. | $14.47 | 2020 | |
| Ibsa Pharma INC. | $14.21 | 2022 | |
| Circassia INC. | $12.35 | 2019 | |
| Almatica Pharma LLC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Durr-E-Shahwaar Sayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.